Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals

Drug Profile

Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals

Alternative Names: Ferumoxytol - Merrimack Pharmaceuticals; MM-398 companion diagnostic

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in USA (IV, Infusion)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Apr 2014 Preliminary efficacy and adverse events data from a phase I pilot study released by Merrimack Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top